FSD1, fibronectin type III and SPRY domain containing 1, 79187
N. diseases: 220; N. variants: 0
Source: ALL
| Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.340 | Biomarker | disease | BEFREE | Dual‑luciferase activity assay indicated that sorcin was the target of miR‑1 in GC. | 31268161 | 2019 | ||||
|
0.340 | AlteredExpression | disease | BEFREE | Functionally, overexpression of miR-1-3p inhibited proliferation and invasion in GC by inhibiting stanniocalcin 2 (STC2) expressions. | 31696489 | 2019 | ||||
|
0.340 | AlteredExpression | disease | BEFREE | We measured miR-1 expression in human GC cell lines and 90 paired primary GC samples, and analyzed the association of its status with clinicopathological features. | 28493075 | 2018 | ||||
|
0.340 | Biomarker | disease | BEFREE | This review aims to provide a summary of recent findings on the miR-1, -133 and -206 family in GC and how this knowledge might be exploited for the development of future miRNA-based therapies for the treatment of GC. | 27349337 | 2016 | ||||
|
0.340 | Biomarker | disease | CTD_human | Methylation status of the 32 randomly selected and 16 potential tumor-related genes was analyzed in 10 primary gastric cancers, and 42 genes (ABHD9, ADFP, ALDH1A3, ANXA5, AREG, BDNF, BMP7, CAV1, CDH2, CLDN3, CTSL, EEF1A2, F2R, FADS1, FSD1, FST, FYN, GPR54, GREM1, IGFBP3, IGFBP7, IRS2, KISS1, MARK1, MLF1, MSX1, MTSS1, NT5E, PAX6, PLAGL1, PLAU, PPIC, RBP4, RORA, SCRN1, TBX3, TFAP2C, TNFSF9, ULBP2, WIF1, ZNF177 and ZNF559) were methylated in at least one primary gastric cancer. | 16367923 | 2006 |